Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)

Journal:

Nature Communications

Published:

2026-01-13

DOI:

10.1038/s41467-025-67950-8

Affiliations:

11

Authors:

16

Go to article

Institutions	Authors	Share
Guangdong Academy of Medical Sciences (Guangdong Provincial People’s Hospital), China	7.000000	0.44
Foshan First People's Hospital, China	1.000000	0.06
Sichuan Cancer Hospital, China	1.000000	0.06
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.06
Dongguan People's Hospital, China	1.000000	0.06
The First Affiliated Hospital, SYSU, China	1.000000	0.06
Hospital and Cancer Center, CQU, China	1.000000	0.06
State Key Laboratory of Respiratory Disease (SKLRD), China	1.000000	0.06
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.06
Genetron Health Technologies Inc., United States of America (USA)	1.000000	0.06

Interested in Oncology and Carcinogenesis?